Provided are high triplet host compounds based on a multiphenylene macrocycle which comprises at least one group L.sup.1 selected from the group consisting of O, S, Se, BR, BRR′, CRR′, SiRR′, and GeRR′ which links two phenylene groups. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.

Provided are high triplet host compounds based on a multiphenylene macrocycle which comprises at least one group L.sup.1 selected from the group consisting of O, S, Se, BR, BRR′, CRR′, SiRR′, and GeRR′ which links two phenylene groups. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.

The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.

The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.

Compounds having chemiluminescent flash and glow properties. Also disclosed are methods using the compounds to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Also disclosed are kits relating to these compounds.

Compounds having chemiluminescent flash and glow properties. Also disclosed are methods using the compounds to generate light, detect and/or quantify enzymes, antigens, and/or nucleic acids. Also disclosed are kits relating to these compounds.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

An antimycin compound and a preparation method and use thereof are provided. The preparation method comprises: fermenting a marine actinomycete (Steptomyces sp.4-7) with a preservation number CCTCCNO: M2020953 to obtain a fermented product and soaking and extracting the fermented product with ethyl acetate to obtain a crude extract; and carrying out separation and purification by normal-phase silica gel column chromatography, reversed-phase MPLC, and semi-preparative reversed-phase high-performance liquid chromatography. The antimycin compound has the advantages of resistance against Botrytis cinerea and Penicillium citrinum.

An antimycin compound and a preparation method and use thereof are provided. The preparation method comprises: fermenting a marine actinomycete (Steptomyces sp.4-7) with a preservation number CCTCCNO: M2020953 to obtain a fermented product and soaking and extracting the fermented product with ethyl acetate to obtain a crude extract; and carrying out separation and purification by normal-phase silica gel column chromatography, reversed-phase MPLC, and semi-preparative reversed-phase high-performance liquid chromatography. The antimycin compound has the advantages of resistance against Botrytis cinerea and Penicillium citrinum.